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The cornea accounts for two-thirds of the refractive power
of the eye. It is a structure composed largely of collagen and
water that is maintained and protected on its anterior and
posterior surfaces by the epithelium and endothelium,
respectively. Transparency and preservation of surface archi-
tecture are both of primary importance. Ocular disease that
compromises the epithelium, in particular, can have devastat-
ing consequences to vision and overall ocular health. The epi-
thelium, several layers thick, is a barrier composed of a tightly
linked network of cells attached by hemidesmosomes and
gap junctions, serving as the eye’s first line of immunological
defense.1 After a corneal abrasion, for example, the eye typ-
ically epithelializes and resurfaces the wound quickly and
uneventfully. In the presence of certain risk factors, including
corneal hypesthesia, diabetic keratopathy, limbal stem cell
deficiency, dry eye disease, exposure keratopathy, andneurotrophic keratopathy from herpetic infections or previ-
ous corneal transplantation, epithelial defects can persist
beyond the usual treatment period despite standard thera-
pies.2,3 In accordance with the literature, when a patient
has been treated for approximately two weeks to no avail,
they are said to have a persistent epithelial defect, or PED.4
Although uncommon, management of patients with PEDs
can be quite challenging and may require an extended fol-
low-up period. This article will serve as a review of current
standard therapies, recently introduced alternative therapies
gaining in popularity, and a look into the newest develop-
ments that may change the way we manage corneal surface
disease.
Standard therapies
The first step in the management of any epithelial abnor-
mality is to determine the etiology of the disease. Thee:
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ondary to exposure keratopathy from thyroid eye disease,
for example, may be vastly different from a patient with
OSD who suffers from graft-versus-host disease (GVHD) or
limbal stem cell deficiency (LSCD) from an alkali burn. In
these cases, treatment of the underlying processes is neces-
sary in order for local therapy for the OSD to be successful.
Aggressive lubrication
This is typically first-line therapy with either high frequency
application of preservative-free artificial tears or sterile oph-
thalmic ointment.2 This may prove to be particularly difficult
with the noncompliant patient.
Discontinuation of medications
An often overlooked reason for a PED may ultimately be
iatrogenic. This is sometimes referred to as ‘‘medicamento-
sa,’’ or toxic keratitis stemming from topical ophthalmic med-
ications themselves. Common offenders tend to be
antibiotics, antivirals, and anti-glaucoma medications; how-
ever preservatives such as benzalkonium chloride ubiquitous
in ophthalmic preparations are usually the real culprit.5,6
Although discontinuation of the offending agent may not
be medically indicated given the ocular circumstance, if indi-
cated, however, shifting to a different agent or stopping alto-
gether may prove to be curative.1
Punctal occlusion
To increase epithelial contact time with lubricating tears
and ointments, patients may benefit from temporary or per-
manent occlusion of the puncta. This is not recommended in
circumstances requiring the continued use of toxic agents, as
mentioned above.
Bandage soft contact lens
The use of soft lenses can be effective in the treatment of
PEDs as they aid in the epithelialization process by protecting
the advancing epithelial cells from being sloughed-off by the
blinking eyelids, as well as by providing anesthetic relief.
They cannot be used alone, however, as these patients are
at risk for infectious keratitis as well as worsening of the epi-
thelial defect from dry eye. Therapy should be supplemented
with preservative-free artificial tears frequently to prevent the
lens from sticking to the ocular surface, as well as a broad
spectrum antibiotic drop. Even with antibiotic coverage,
there is still a risk for infection,7–9 and neurotrophic corneas
may delay a patient’s presentation back to the clinic; there-
fore close follow-up is a necessity in this population.
Pressure patching
This is a common treatment modality for large corneal
abrasions, and it is an alternative therapy for PEDs offering
similar benefits conferred by the contact lens use. Drawbacks
include the need to see patients every 24–48 h as prolonged
patching may impair wound healing10,11 while also being a
risk factor for infectious keratitis. Given the typical length of
time involved in resolution of these defects, requiring suchfrequent examination may be inefficient for the practitioner
and taxing on the patient.
Debridement
At times, the leading edges of the healing epithelium may
thicken and become stagnant, impeding subsequent growth
across the defect. In this case, the leading edges may be
removed thereby permitting the more peripheral, younger,
and healthier epithelium to continue its migration across
the cornea.
Tarsorrhaphy
Less frequently implemented, but highly effective is the
use of temporary or permanent tarsorrhaphy in the manage-
ment of the PED. This therapy limits corneal exposure and
permits repair even in the harshest environments. Simple lid
taping, especially in the evening, is effective for 24–48 h at
a time, while lid opposition with cyanoacrylate glue may last
up to 5 days. Temporary suture tarsorrhaphy with bolsters
may last up to 6 weeks which can be less intimidating for
the patient concerned about cosmetic appearance from a
permanent procedure. Some specialists advocate for the
injection of botulinum toxin A into the levator muscle to keep
the surface covered for months at a time still permitting fre-
quent ocular examination, if needed, but without the need to
surgically close the eyelids.12 Each of these options can be
conveniently performed in a minor procedure room.
Newer therapies
Amniotic membrane grafting
Amniotic membrane patching and grafting have been
shown to decrease inflammation, vascularization, and scar-
ring of the cornea while promoting the re- epithelialization
of the cornea.13–15 It is thought to achieve this through the
release of certain growth factors and proteins. It is now read-
ily available commercially in fresh frozen (Amnion; Bio-Tissue,
Inc., Miami, FL) and freeze-dried forms (Ambiodry2; IOP
Ophthalmics, Costa Mesa, CA). The tissue may be sutured
or glued in place with fibrin glue.16 There is also a self-retain-
ing amniotic membrane device that can be placed in the
office (ProKera; Bio-Tissue, Inc., Miami, FL).
Autologous serum (AS)
Standard therapies for PEDs mentioned above such as arti-
ficial tears, punctal occlusion, and tarsorrhaphy fail to intro-
duce to the cornea the essential growth factors found in
natural tears. Topical tears formulated from a patient’s own
centrifuged serum is gaining popularity, and studies continue
to report favorably on its efficacy in the management of many
types of OSD, including PED. 47–83% of PEDs recalcitrant to
standard therapies have been shown to be closed within four
weeks of initiating autologous serum tear therapy.3,17–21 Its
beneficial effects are thought to be due to high concentration
of key components involved in the proliferation and migration
of the epithelium; components that are found in varying con-
centrations in natural tears, but are generally scarce or lacking
in artificial tears. These factors include vitamin A, vitamin E,
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(TGF-B), platelet-derived growth factor (PDGF), fibroblast
growth factor (FGF), fibronectin, substance P, insulin-like
growth factor (IGF), and nerve growth factor.3 Unfortunately,
obtaining autologous serum tears is not without its difficulties.
There is no validated, standardized protocol for developing
the tears from whole blood, although Liu and colleagues have
offered what they believe to be their optimized protocol.22 As
a result, regulatory restrictions on the manufacturing of autol-
ogous serum tears continue to keep this beneficial therapy
from more mainstream use both on national and international
levels.23 In addition, it is not known what is the optimal concen-
tration of autologous serum eye drops. Although 20% autolo-
gous serum is a popular concentration (thought to be optimal
because this percentage dilutes the concentration of TGF-B to
that which is the normal level in the tears), other concentrations
such as 50% and 100% are used by some authors. It is possible
that different OSD entities may respond differently to different
concentrations, but there have been no clinical trials that have
offered us this information at this time.Other whole blood-derived products
Not all patients are ideal candidates for autologous serum:
this includes those patients who are systemically ill, are in
poor general health, or suffer from active infection; or those
patients with disease whereby excess pro-inflammatory cyto-
kines may be present in the serum, such as in a patient with
GVHD or the Sjogren Syndrome.24 Alternative therapies
gaining more recent attention include umbilical cord blood
serum (CBS) tears and platelet-rich fibrin (PRF) tears. Some
studies have shown CBS to be more efficacious than autolo-
gous serum in the resolution of epithelial defects, thought to
be due, in part, to elevated growth factor levels and more
anti-inflammatory cytokines as compared to autologous
serum. Vajpayee and colleagues25 conducted a prospective,
randomized, controlled clinical trial of 60 eyes of 59 patients
assigned to either the umbilical cord serum treatment group
or the autologous serum control group in the management of
persistent corneal epithelial defects. They found that the
cord serum group had significantly faster healing times and
a greater number of defects with complete re-epithelializa-
tion as compared to the autologous serum group. Yoon
et al.26 compared the difference in therapeutic effect
between autologous serum and umbilical cord serum in the
treatment of dry eye syndrome and found that the cord
serum was more effective at decreasing symptoms and kera-
toepitheliopathy in severe dry eye syndrome as well as
increasing goblet cell density in the Sjogren Syndrome. Its
efficacy is also well substantiated for numerous conditions
including but not limited to dry eye, PEDs, recurrent corneal
erosions, chemical burns, and neurotrophic keratopathy.24
One primary advantage of making tears from CBS is the fact
that blood taken from the umbilical vein can supply tears to
many patients all at once; and be available for pickup imme-
diately upon prescribing, rather than the alternative time-
consuming process involved in having a patient undergo
phlebotomy followed by waiting for ophthalmic preparation.
The chief disadvantage, however, is the risk of transmission of
blood-borne infectious disease from pregnant donors. For
this reason the blood must be tested rigorously before
becoming available to a patient.26 This may ultimately proveto be less desirable to some patients. A newer alternative to
AS is platelet rich plasma tears (PRP). Platelets are better rec-
ognized for their role in hemostasis and vascular injury, but
they also play a significant part in wound repair throughout
the body, influencing angiogenesis and inflammation. The
alpha-granules released from activated platelets contain
growth factors and cytokines including PDGF, EGF, TGF-B,
FGF, and IGF-1. It is thought that because PRP contains a
higher concentration of these vital epitheliotrophic factors
than serum, this therapy may prove to be more valuable than
AS. In the first comparison of AS to PRP, Kim and col-
leagues27 found that the rate of epithelial healing was signif-
icantly greater in the PRP group. PRP is similar to AS in that it,
too, has no standardized and validated protocol making its
availability to treating physicians problematic.
Limbal stem cell transplantation
If the etiology of the PED is due to the deficiency of the
stem cells that are responsible for repopulating the epithe-
lium, then surgical replacement with stem cell allo- or auto-
grafts is indicated. This is frequently seen in conditions such
as ocular cicatricial pemphigoid, Stevens Johnson Syndrome,
and severe alkali burns.28,29 However, care must be taken to
assess whether a stem cell transplant will have a reasonable
likelihood of surviving given the ocular surface condition. A
major disadvantage of this procedure is that allografts of lim-
bal stem cells require that the patient is systemically immuno-
suppressed30 and long-term follow-up of these patients has
demonstrated disappointing survival rates.31,32 Recently,
Boston keratoprosthesis implantation has emerged as an
effective modality for visual rehabilitation in such
patients.33,34
Scleral contact lenses35
Becoming more frequently utilized in dry eye disease sec-
ondary to GVHD or chemical burns, the Boston Scleral Lens,
now referred to as the PROSE (Prosthetic Replacement of the
Ocular Surface Ecosystem; Boston Foundation for Sight,
Needham, Massachusetts) has demonstrated efficacy in the
treatment of PEDs.36 It is known that a continuous supply
of oxygen is needed to support the repair and growth of a
healthy epithelium. During sleeping hours, however, closed
eyelids decrease the partial pressure of oxygen on a contact
lens surface which is even further attenuated as this fluid dif-
fuses through the lens matrix to the ocular surface. In the
PROSE, the fluid-tear interchange under the haptic provides
an additional route for oxygen delivery during sleep that ban-
dage contact lenses and pressure patching cannot provide.
Its unique design integrates a series of radial venting chan-
nels between the haptic and the sclera that function as a
safety valve through which tears get aspirated alone, without
air bubbles, and without the development of suction.37 Of
course similar to other ocular surface lenses, eyelid-corneal
friction is also eliminated. Consideration of concurrent pro-
phylactic antibiotic therapy is warranted if used for PED.
Therapies in development
Novel therapies recently being investigated are beginning
to show promise in the treatment of the nonhealing corneal
epithelium.
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Thymosin beta 4 is a synthetically produced copy of a 43-
amino acid peptide found in most tissue types, with the high-
est concentration being in blood platelets and white blood
cells, and extracellulary in blood plasma and wound fluid.38
It has been demonstrated to promote corneal wound re-epi-
thelialization, diminish inflammation, and inhibit apoptosis.
Its most unique property is its anti-inflammatory effects,
although the precise mechanism is still under investigation.
In vivo studies suggest that it interrupts the transcription
necrosis factor- alpha (TNF-alpha) signaling pathway,
decreasing levels of other transcription factors including
nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-kB) and its downstream cytokines are shown to be
destructive to the cornea. TNF-alpha is a well-known, potent
pro-inflammatory mediator involved in many ocular diseases
(infectious, auto-immune, and sterile inflammatory). Therapy
directed at modulating this particular pathway may have ben-
eficial effects on the eye that spread far beyond ocular sur-
face disease. Sosne and colleagues,39 for example, are
currently working on a TB4 drug delivery system through spe-
cially formulated hydrogel bandage contact lenses. There is
limited data with human trials, as studies are limited to
FDA-approved compassionate usage only, although results
thus far seem promising.39,40Nexagon
Nexagon (connexin43 antisense gel; CoDa Therapeutics,
Inc., New Zealand) is among the latest of novel drugs aimed
at healing PEDs, in particular in those due to severe ocular
burn or chemical injury. Connexin43 is one of the 20 human
connexin proteins that comprise cellular gap junctions. Gap
junctions provide a direct communication between cells, per-
mitting transfer of molecules and ions which can subse-
quently influence a multitude of signaling pathways.
Preclinical models have shown that the decreased translation
of connexin43 has led to a decrease in edema, inflammation,
apoptosis, and overall improved healing.41 This has been
observed in skin incisions, skin burns, the cornea, cardiac
ischemia, and the central nervous system.41 Connexin43
gap junctions also seem to play a role in bystander death, a
term used to define the process of apoptotic spread among
cells. Dying cells have been shown to induce apoptosis in
nearby cells in direct proportion to the number and density
of gap junctions within the dying cell.42 This process of cell
death leads to stagnation of wound closure or enlargement
of wound defects, referred to as lesion spread.2 Results from
compassionate use non-controlled human trials with Nexa-
gon in chemical and thermal ocular injury leading to PEDs
have been encouraging.41Mesenchymal stem cells
Autologous adipose-derived mesenchymal stem cells
(MSCs) have recently been introduced as a potential break-
through therapy for PED and stromal ulceration. These cells
are multipotent and therefore have the capacity to differenti-
ate into any human cell type. Although used experimentally
in animal research,43 the first known application in a human
cornea was published in 2011 of a patient with keratoconusand a persistent epithelial defect following trauma.44 He was
scheduled for a penetrating keratoplasty due to his high risk
for perforation, and he was offered this experimental therapy
in the interim before surgery. The defect successfully closed
within a month without further sequelae. The mechanism of
action remains unclear, although several theories exist.
Whether it will be secretion of trophic factors and cytokines
influencing neighboring cells, its immunomodulatory effects,
or its direct differentiation into corneal stromal cells, autolo-
gous MSC transplantation calls for further investigation into
its mechanism and application in corneal regenerative
therapy.
Conclusion
Managing the persistent epithelial defect can be both an
arduous task for the ophthalmologist and a burden to the
patient; the conventional therapies tend to be ineffective
thereby prolonging patient discomfort and their diminished
visual acuity, as well as requiring frequent clinic follow-up at
a cost to society and worker productivity. Interestingly, one
study has shown that the length of time a defect is left open
and unhealed is directly proportional to the time it will take
for the defect to be fully repaired.3 This would argue for pro-
phylactically managing patients at high risk for developing
PEDs: it may be prudent to be more aggressive at the onset
of epithelial compromise in certain patient populations.
There is an encouraging future for the management of persis-
tent epithelial defects, as alternative treatment modalities
are proving beneficial and efficacious, while promising newer
therapies are under investigation.
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